Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
- Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
- Over 80% of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S.
- Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).